| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, University of Birmingham and Heartlands Hospital (P.G.M., F.M.F., G.V., R.C., A.H., C.L.M., P.M.S.C., A.H.B., S.K.), Edgbaston Birmingham, United Kingdom B15 2TH; and Glaxo-SmithKline, New Frontiers Science Park (S.A.S.), Harlow, United Kingdom CM19 5AW
Address all correspondence and requests for reprints to: Prof. S. Kumar, Warwick Medical School, University of Warwick, Coventry, United Kingdom CV4 7AL. E-mail: sudhesh.kumar{at}warwick.ac.uk.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
/FIZZ 1 and RELMß/FIZZ 2) of FIZZ (found in inflammatory zone) that are believed to be involved in inflammatory processes (1, 2, 3). Previous studies have shown that in mice, resistin impairs glucose tolerance and insulin action and inhibits adipogenesis in murine 3T3-L1 cells (1, 4, 5, 6, 7). Therefore, resistin has also been proposed as an adipocyte secreted factor that is thought to link obesity and type 2 diabetes (2). The role of resistin in human obesity remains controversial. Previous resistin mRNA expression studies have produced conflicting reports about the level of expression of this gene in human adipose tissue (8, 9, 10, 11). However, recent studies also indicate higher levels of expression of both gene and protein in central adipose tissue depots, supporting a role for resistin in linking central obesity to diabetes (12). Thiazolidinediones (TZD) are a class of antidiabetic drugs that enhance target tissue sensitivity to insulin (4). Lazar and co-workers (1) were the first to demonstrate that both resistin mRNA and protein were down-regulated by TZDs in vitro, with the majority of subsequent in vivo data supporting these observations (13, 14, 15). Furthermore, in their experiments, recombinant resistin induced insulin resistance both in vivo and in vitro, an effect that was blocked by antiresistin antibodies. These data suggested a potential mechanism for obesity-related insulin resistance and also indicated a new mechanism of action for TZDs. These findings support the hypothesis that resistin may be a protein that limits obesity at the expense of glucose tolerance, at least in rodent models.
Although resistin appeared to be a potential candidate protein linking excess adiposity and insulin resistance in rodent models, many human studies described low levels of resistin mRNA expression in adipose tissue and concluded that this molecule is unlikely to be an important factor linking human obesity to insulin resistance (8, 9, 10). Our previous studies have, however, shown that resistin mRNA and protein expression are significantly increased in human central adipose tissue depots (both omental and sc) compared with thigh and breast adipose tissue (11, 12). In addition, we confirmed increasing resistin mRNA expression with obesity, in agreement with previous findings by Savage et al., (8). These findings were not related to the contamination of adipose tissue samples by mononuclear blood cells, which are known to express resistin (8, 9, 12).
It is clear that further studies are needed to understand the role of resistin in human obesity and type 2 diabetes. Although our previous human resistin mRNA and protein expression adipose tissue studies have implicated this adipocytokine as a potential pathogenic factor in central adiposity, its functional effects on glucose and lipid metabolism and its regulatory role by insulin remain unknown. The present study therefore examined whether resistin was simply a marker of diabetes status or was a regulated and functionally important cytokine that potentially contributed to the pathogenesis of obesity-related type 2 diabetes. We also examined the relationship of resistin to subclinical inflammation in view of studies demonstrating the expression of resistin in macrophages (8, 9). Therefore, to extend our investigations we validated a commercially available ELISA and then assessed serum concentrations of resistin in nondiabetic and type 2 diabetic subjects. Serum resistin was also assessed for correlations with other clinical and biochemical parameters, including fasting serum glucose, insulin, leptin, hemoglobin A1c (HbA1c), and C-reactive protein concentrations as well as anthropometric data. Next, we examined the in vitro effects of insulin and TZDs on resistin expression in isolated human adipocytes. Finally, we examined the effect of recombinant human resistin on glucose uptake, lipolysis, and lipogenesis in human differentiated preadipocytes.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Serum resistin levels were examined in 45 nondiabetic subjects [9 women and 36 men; age, 40.2 ± 12.8 yr (mean ± SD); body mass index (BMI), 33.04 ± 10.64 kg/m2] and 34 type 2 diabetic subjects (5 women and 29 men; age, 54.3 ± 13.03 yr; BMI, 30.5 ± 6.3 kg/m2). Subcutaneous abdominal adipose tissue was obtained from a human population (female/male ratio, 15:3; age, 43.7 ± 5.2 yr; BMI, 25.3 ± 2.7 kg/m2). Subjects providing fat samples were not receiving endocrine therapy (e.g. steroids, hormone replacement therapy, or T4) or any antihypertensive therapy and were not diabetic. All studies were carried out with the approval of the local ethics committee, and patients provided informed consent.
Collection and analysis of serum samples
For the collection of blood, samples were taken after a 12-h fast for the determination of serum glucose, insulin, leptin, resistin, HbA1c, and C-reactive protein concentrations. At the same time, all anthropometric data were collected. Specific measurement of serum HbA1c was performed using routine laboratory procedures. Insulin was analyzed by a solid phase enzyme-amplified sensitivity immunoassay (Medgenix Ins-ELISA, BioSource, Nivelles, Belgium). Insulin resistance [determined by homeostasis model assessment (HOMA)] and ß-cell function were derived using the HOMA equation (16). C-Reactive protein was measured using a particle-enhanced immunological assay (Roche, Basel, Switzerland).
Isolation and cell culture of mature adipocytes
Subcutaneous abdominal adipose tissue was digested as previously described to isolate mature adipocytes and preadipocytes (17). After isolation of these cell types, mature adipocytes (n = 14) were cultured in phenol red-free DMEM/Ham’s F-12 medium containing 15 mmol/liter glucose, penicillin (100 U/ml), and streptomycin (100 µg/ml). Compacted (1-ml) aliquots of adipocytes (500,000 cells) were maintained in medium (5 ml) for 48 h and treated with insulin alone (1–1 µM), RSG alone (0.1 nM to 10 µM; GlaxoSmithKline, Harlow, UK), or insulin (1–1 µM) in combination with RSG (10 nM). Additionally, a time-course study was undertaken to assess changes in mRNA and protein secretion of resistin at 4, 12, and 24 h with control and insulin-treated adipocytes (1 and 100 nM). Adipocytes maintained in untreated medium for 48 h were used as the controls. The viability of adipocytes was assessed using the trypan blue dye exclusion method as previously documented (Sigma-Aldrich Corp., Poole, UK) (16). After treatment, the medium and adipocytes were separated by centrifugation (360 x g for 2 min). The medium was removed, aliquoted, and stored at -70 C.
Differentiation of preadipocytes
Abdominal sc preadipocyte cells (n = 7) were grown in 12-well plates to confluence in DMEM/Ham’s F-12 medium containing 15% fetal calf serum, penicillin (100 U/ml), streptomycin (100 µg/ml), and transferrin (5 µg/ml). At confluence, preadipocytes were differentiated in DMEM/Ham’s F-12 phenol-free medium containing glucose (1000 mg/liter), penicillin (100 U/ml), streptomycin (100 µg/ml), transferrin (5 µg/ml), T3 (0.2 nM), panthenoate (17 µmol/liter), biotin (33 µmol/ml), insulin (100 nM), and cyclodextran-coated cortisol (100 nM) (18, 19). This chemically defined, serum-free medium was changed every 2 d for 12 d. Cells were also treated with 1-methyl-3-isobutylxanthine during the first 4 d of differentiation as previously described (19). Cells were treated in triplicate with varying concentrations of recombinant resistin (Research Diagnostics, Flanders, NJ; 0.1, 1, 10, 30, and 50 ng/well) during differentiation of the preadipocytes. Control was taken as preadipocytes maintained in differentiation medium without recombinant resistin treatments for the duration of the study. Conditioned media from the differentiating preadipocytes were collected every other day for the duration of the 12 d and stored at -70 C. Additionally, sc preadipocytes were differentiated until d 11 in chemically defined medium alone and subsequently treated with recombinant resistin (30 ng) for 24 h.
Western blot analysis
Homogenized human adipose tissue and adipose cells were resuspended in 4% sodium dodecyl sulfate as previously described (17). In addition, a human lung carcinoma cell line (ECACC 86012804) and human mucosal colonic tissue were used as positive controls for RELM /FIZZ 1 and RELMß/FIZZ 2, respectively. Western blot analysis was performed using a method previously described (20). In brief, 10–60 µg protein were loaded onto a 4–20% precast gel (Bio-Rad, Poole, Dorset, UK), and human RELM /FIZZ 1 and RELMß/FIZZ 2 polyclonal primary antibodies were used (1:500 and 1/250, respectively; Alpha Diagnostics, Princeton, NJ). Both RELM/FIZZ 1 and RELMß/FIZZ 2 were developed using antirabbit horseradish peroxidase secondary antibodies (Biogenesis, Poole, UK). Equal protein loading for these samples was confirmed by examining actin expression using Western blotting, as previously described (21). A chemiluminescent detection system (ECL/ECL+, Amersham Pharmacia Biotech, Little Chalfont, UK) enabled visualization after exposure to x-ray film.
Protein assay
Protein concentrations were determined using the Bio-Rad DC (detergent-compatible) protein assay kit (22). Adipocyte protein samples were also assessed to determine that there was no statistically significant variation between the control and treatment regimens, thus indicating that the changes observed in the secretion of resistin were not due to variations in protein between samples.
Serum resistin concentrations
Serum samples were analyzed for resistin in nondiabetic (mean age, 40.2 ± 12.8 yr; mean BMI, 33.0 ± 10.6 kg/m2) and type 2 diabetic samples (mean age, 54.3 ± 13 yr; mean BMI, 30.5 ± 6.3 kg/m2) using the human resistin ELISA assay from Phoenix Pharmaceuticals (San Francisco, CA). The measurement of resistin secreted from abdominal sc adipocytes in conditioned medium samples was made after dilution with assay buffer before analysis. Due to the theoretical possibility that cross-reactivity with other RELMs may occur, we assessed cross-reaction using RELM/FIZZ 1 and RELMß/FIZZ 2 partial peptides (Alpha Diagnostics Eastleigh, Hampshire, UK). Known quantities of recombinant resistin (Research Diagnostics) were also used to determine recovery within the assay, using assay buffer as well as serum coincubated with RELM/FIZZ 1 and RELMß/FIZZ 2 partial peptides ( Diagnostics).
Incorporation of glucose into differentiated preadipocytes
For assessment of glucose uptake, a modified method of Dole and Meinertz was used (23). The differentiated preadipocytes were incubated with and without treatments, 14C-labeled glucose (Amersham Pharmacia Biotech) and unlabeled glucose (5 mmol/liter) with a concentration of 0.5 mmol/liter in the chemically defined medium on the final day of incubation. After 14 h at 37 C, the medium was removed, and preadipocytes were extracted in 2% sodium dodecyl sulfate containing 25 mM Tris-HCl (pH 6.8; a 5-µl aliquot was taken for protein assay). The amount of labeled 14C released from the cells as CO2 was also measured. Filter disks (grade 1M chromatography paper, 20 mm diameter, Whatman, Cambridge, UK) presoaked in sodium hydroxide (1 M) to absorb CO2 were attached above each well of the culture plates. These filters remained attached during the period of the experiment. Subsequently, the extracted preadipocytes and filter disks were placed in scintillation fluid (Opti-Phase 3, Wallac, Milton Keynes, UK), and the radioactivity was determined using a liquid scintillation counter.
Lipolysis studies in differentiated preadipocytes
Conditioned media collected during the course of differentiation of the preadipocytes were assessed for glycerol production as a measure of lipolysis (micromoles per milliliter) using a commercially available colorimetric kit (Randox Laboratories, Co. Antrim, UK).
Leptin secretion in differentiating preadipocytes
Conditioned medium samples collected during the course of differentiation were assayed for leptin secretion, as a marker of differentiation, using an RIA kit (Linco Research, Inc., St. Charles, MO). In addition, serum leptin analysis was performed in the nondiabetic and type 2 diabetic subjects.
Lipid staining of differentiated preadipocytes
Lipid staining was performed using a modified method of Culling et al. (24). Briefly, on d 12 differentiated preadipocytes were washed with Hanks’ Balanced Salt Solution and stained with 2.5% Oil Red O (Gurr Ltd., London, UK) for 15 min at room temperature. After brief treatment with 60% isopropanol (Fisher Scientific Ltd., Loughborough, UK) at room temperature, cells were washed with distilled water and viewed with a light microscope. Differentiation of preadipocytes was determined by photographic assessment of the accumulation of lipid over time.
Extraction of adipocyte RNA and quantitative RT-PCR
RNA was extracted from treated isolated adipocytes using the GenElute total mammalian RNA kit (Sigma-Aldrich Corp.), which included a deoxyribonuclease digestion step to remove any contaminating genomic DNA. One microgram of RNA from each sample was reverse transcribed using avian myeloblastosis virus reverse transcriptase (Promega, Southhampton, UK) and random hexamers in 20-µl reaction volumes according to the manufacturer’s instructions.
mRNA levels were determined using an ABI 7700 real-time PCR Sequence Detection system (PE Applied Biosystems, Foster City, CA), as previously described (25). The reactions were performed in 25-µl volumes on 96-well plates in reaction buffer containing TaqMan Universal PCR Master Mix (PE Applied Biosystems), 3 mM Mn(Oac)2, 200 µM deoxy-NTPs, 1.25 U AmpliTaq Gold polymerase (PE Applied Biosystems), 1.25 U AmpErase UNG (PE Applied Biosystems), 150 nmol TaqMan probe, 900 nmol primers, and 50 ng cDNA (except for resistin assay for which 115 ng cDNA were used). Quantitative primer and probe sequences for resistin and CD45 genes were analyzed using previously detailed sequences (11, 12). All reactions were multiplexed with the housekeeping gene 18S, provided as a preoptimized control probe (PE Applied Biosystems), enabling data to be expressed in relation to an internal reference to allow for differences in RT efficiency. Data were obtained as Ct values according to the manufacturer’s guidelines (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and were used to determine 
Ct values (Ct = Ct of the target gene minus Ct of the housekeeping gene). Measurements were carried out on at least three occasions for each sample. To exclude potential bias due to averaging data that had been transformed through the equation 2-Ct, all statistics were performed at the Ct stage.
Statistical analysis
For analysis of serum resistin and gene expression data, statistical analysis was undertaken using unpaired t tests unless otherwise stated, where data were analyzed using nonparametric tests. Protein expression data for control and treatment regimens were compared using ANOVA. The threshold for significance was P < 0.05. The data in the text and figures are presented as the mean ± SEM unless otherwise stated.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Recombinant resistin was used to generate a standard curve with the resistin ELISA from Phoenix Pharmaceuticals and produced a corresponding curve, as documented previously with the resistin peptide standards provided in the kit. Known concentrations of recombinant resistin (5, 10, 12, and 15 ng/ml) were also added to pooled serum (29.9 ng/ml) to determine whether the expected concentration correlated closely with the actual observed value. In serum, the recovery of spiked resistin was between 90–98% efficient (expected value for pooled serum coincubated with 10 ng/ml recombinant resistin, 39.9 ng/ml; actual observed values, 38.35 ± 1.2 ng/ml).
Resistin assay validation: cross-reactivity with RELMs
Known concentrations of RELM partial peptide (12, 15, and 40 ng/ml) and recombinant resistin (25 ng/ml) were added to an aqueous solution. However, the addition of RELM did not interfere with the resistin ELISA assay (Phoenix Pharmaceuticals). Similar findings were observed for the RELMß partial peptide at the same concentrations (data not shown). When RELM and RELMß peptides were added to pooled serum samples, these findings showed that neither peptide altered the known serum concentrations of resistin measured in the absence of peptides in the resistin ELISA. Again, the addition of RELM and RELMß peptides to a serum matrix containing recombinant resistin (25 ng/ml) did not affect the expected resistin concentration (data not shown).
Comparison of serum resistin in diabetic with nondiabetic subjects
Comparison of fasting serum resistin in type 2 diabetic and nondiabetic subjects showed that type 2 diabetic patients had higher resistin levels than nondiabetic subjects [diabetic subjects, 16.6 ± 0.89 ng/ml (mean ± SEM); nondiabetic subjects, 13.5 ± 0.5 ng/ml; P = 0.004; Fig. 1
]. Additionally, we performed stepwise multiple regression analysis using resistin as the dependent value with independent values as follows: C-reactive protein, insulin, BMI, waist circumference, diabetic status, leptin, and insulin resistance using HOMA (26). This analysis determined that C-reactive protein was the only significant predictor of resistin using a Spearman correlation (Fig. 2; P = 0.04; r = 0.39). There was no significant ethnic difference in serum resistin levels between the Caucasian and Indo-Asian subjects with or without type 2 diabetes. No gender differences were noted in serum resistin levels. Serum leptin increased with adiposity in the nondiabetic subjects (Fig. 3). Serum leptin levels were not significantly altered by diabetic status.
|
|
|
In cultured mature human adipocytes, exposure to insulin concentrations up to 1 µM had no effect on resistin mRNA expression [control Ct, 20.69 ± 0.31 (mean ± SE); 100 nM insulin Ct, 20.49 ± 0.52; 1 µM insulin Ct, 20.61 ± 0.34; Table 1]. Furthermore, resistin mRNA expression was unaltered by RSG alone (10 nM RSG Ct, 20.43 ± 0.55) or insulin in combination with RSG (100 nM insulin plus 10 nM RSG Ct, 20.53 ± 0.36; Table 1).
|
Ct, 26.81 ± 0.78 (mean ± SE); 1 nM insulin Ct, 26.83 ± 0.88; 100 nM insulin Ct, 27.72 ± 0.69]. CD45 mRNA expression was also not different in the samples with RSG alone (10 nM RSG Ct, 27.2 ± 0.92) or in combination with insulin (100 nM insulin plus 10 nM RSG Ct, 27.53 ± 0.52). Regulation of resistin secretion in sc adipocytes and effects of RSG
In contrast to the lack of effect on resistin mRNA expression, insulin stimulated resistin secretion in adipocytes in a concentration-dependent manner, with maximal stimulation observed at 1 µM insulin [control, 1215 ± 87 pg/ml (mean ± SEM); 1 nM insulin, 1414.0 ± 89 pg/ml; 10 nM insulin, 1478 ± 29 pg/ml (significant increase, P < 0.01); 100 nM insulin, 1545 ± 109 pg/ml (significant increase, P < 0.01); 1 µM insulin, 1797 ± 107 pg/ml (significant increase, P < 0.001); Fig. 3
]. The time-course study (4–24 h) indicated that resistin secretion was only significantly stimulated by insulin at 24 h with 100 nM insulin (Table 2). RSG alone did not influence resistin secretion at any concentration up to 10 µM (10 µM RSG, 1139 ± 93 pg/ml; 10 nM RSG, 1195 ± 213 pg/ml). RSG (10 nM) significantly reduced the insulin-mediated increase in resistin production across the entire range of concentrations studied (P < 0.001; Fig. 4).
|
|
Western blotting determined that both RELM and RELMß were recognized by the antibodies in their respective positive control lanes (10 µg protein/well; Fig. 5, I and II). However, neither RELM nor RELMß was expressed in adipose tissue or isolated adipose cells (10–60 µg protein/well).
|
Chronic treatment of recombinant resistin in differentiated sc preadipocytes reduced glucose uptake and incorporation into lipid in a concentration-dependent manner (control, 17,897 ± 735 dpm; 30 ng/ml recombinant resistin, 14,984 ± 782 dpm; P < 0.05; Fig. 6). At lower concentrations (0.1–1 ng/ml) of recombinant resistin, no effect on lipogenesis rate was observed. Resistin had no significant effect on 14CO2 released from 14C-labeled glucose. The acute effect (14 h) of recombinant resistin in differentiated sc preadipocytes was also examined. Recombinant resistin treatment reduced glucose uptake in the differentiated sc preadipocytes (controls, 17,897 ± 735 dpm; 30 ng/ml recombinant resistin, 14,001 ± 1,006 dpm; P = 0.0261).
|
Assessment of glycerol release on d 12 of the differentiation studies revealed that resistin had no effect on lipolysis compared with controls (Table 3). Chronic treatment with recombinant resistin over time (12 d) did not alter lipolysis. Acute exposure to resistin also had no effect on lipolysis (data not shown).
|
Previous rodent studies indicate that recombinant resistin inhibits differentiation (4); therefore, this may limit obesity at the expense of diabetes. To study this phenomenon in human cells, leptin was assessed as a time-dependent marker of differentiation in the abdominal sc preadipocytes. These studies determined that the differentiating sc preadipocytes increased leptin secretion progressively over the 12-d time course. Resistin had no effect on leptin secretion (Table 4).
|
Lipid accumulation was assessed as another marker of differentiation. Differentiating preadipocytes (in the presence or absence of recombinant resistin) accumulated lipid over time. No difference was observed in the accumulation of lipid by differentiating preadipocytes with varying concentrations of recombinant resistin (Fig. 7).
|
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
/FIZZ 1 and RELMß/FIZZ 2 partial peptides in the resistin assay were determined. Our studies confirmed that RELM/FIZZ 1 and RELMß/FIZZ 2 partial peptides at varying concentrations in either aqueous solution or serum did not interfere significantly in the resistin assay. Similarly, recombinant resistin was used to assess recovery in the ELISA, and an overall 90–98% recovery was measured. Serum resistin was about 20% higher in type 2 diabetic subjects compared with nondiabetic subjects. However, in contrast to the strong correlation shown previously between BMI and leptin, also noted in this study, such a relationship was not observed with serum resistin (27, 28). These data suggest that in human diabetes factors other than obesity and serum insulin are likely to be the major determinants of serum resistin. In contrast, recent studies of human resistin protein expression have suggested that both adiposity and insulin are important determinants of increased resistin levels in lean and obese subjects (29). Furthermore, recent molecular genetic analysis for single nucleotide polymorphisms in the resistin gene implicate both BMI and insulin sensitivity in nondiabetic subjects, but not type 2 diabetic subjects (30, 31, 32).
Additional studies using stepwise multiple regression analysis with resistin as the dependent value, examined all biochemical and anthropometric factors as independent variables (including fasting glucose, leptin, insulin levels, and diabetic status), determined that C-reactive protein was the only significant predictor of resistin within this cohort. These data therefore indicate that in human subjects, resistin is associated more closely with inflammation.
Although no human studies have been reported to date, the role of resistin as a factor secreted as part of an inflammatory response has been examined in two recent mouse studies. These studies have addressed the effect of lipopolysaccharide (LPS), a compound of the cell wall of Gram-negative bacteria, and demonstrated that it induces an inflammatory reaction that may alter resistin expression. These studies, however, yielded conflicting results, with Rajala et al. (33) finding that LPS had no effect on resistin expression, whereas Lu et al. (34) suggested that resistin mRNA expression rose in response to LPS. The apparent difference may relate to several factors, including dose regimen and the animal model used. It should also be noted that the time point at which resistin mRNA expression was evaluated differed between the two studies, which may have influenced the findings. Lu and co-workers (34) measured resistin mRNA expression at an early time (1–8 h) and noted an increase, whereas Rajala et al. (33) examined the effect of LPS on resistin mRNA expression after 24 h. As LPS induces acute phase reactants over the first few hours, such a rise in resistin mRNA expression may be lost by 24 h postinjection. Further studies are required to examine this in more detail, as the present study certainly suggests a potential role for resistin as a proinflammatory factor, at least in humans.
We also examined the direct effect of insulin on adipose tissue to extend our previous findings of resistin gene and protein expression in human adipose tissue (11, 12). In the present study we determined the time course of resistin expression and secretion in cultured adipocytes and then assessed the effect of insulin and RSG on resistin expression in these human adipose-derived cells. Our data demonstrate that the expression of both protein and message were closely related over short periods of time (up to 12 h), but at 24 h, protein secretion increased while resistin mRNA remained unchanged. These results imply that resistin protein synthesis, and hence circulating concentrations, may be modified by posttranscriptional as well as transcriptional mechanisms. This apparent lack of correlation between resistin mRNA and protein in adipocytes has also been observed in mouse model studies (2, 34).
It is well established that TZDs, including RSG, function as potent insulin-sensitizing agents in vivo by increasing insulin-dependent glucose uptake and reducing hepatic glucose output (26, 35, 36, 37). TZD has also been shown to reduce resistin expression in 3T3-L1 adipocytes and adipose tissue in vivo (2). Our data indicate that, as previous rodent model data suggest, resistin secretion from sc abdominal adipocytes increases under hyperinsulinemic conditions, and that this rise is mitigated by TZDs such as RSG. The regulation of resistin expression by insulin and RSG also suggests that resistin may have a paracrine or autocrine effect in adipose tissue, a possibility that requires further study. The mechanism by which RSG suppresses insulin-stimulated, but not basal, resistin secretion from adipocytes is not clear. A recent disclosure that RSG reduced resistin expression and secretion in human macrophages in vitro together with the identification of a putative peroxisome proliferator-activated receptor-binding site in the promoter of the resistin gene strongly support the idea that the resistin gene can be directly transcriptionally regulated by the peroxisome proliferator-activated receptor 
-mediated mechanism (38). However, whether RSG therapy regulates circulating resistin in either nondiabetic or type 2 diabetic subjects in vivo remains to be determined.
In rodent models in vivo and in the murine 3T3-L1 adipose cell line, Lazar and co-workers (2) demonstrated that recombinant resistin reduced glucose uptake. To determine whether resistin exerts similar effects in human tissue, we examined the effects of recombinant human resistin on parameters of glucose and lipid metabolism in human adipose cells. The effects of recombinant resistin on lipogenesis and lipolysis were investigated in differentiated preadipocytes. Our findings suggest that resistin caused a modest concentration-dependent impairment of glucose metabolism after both acute and chronic exposure to the protein. Again, as with our gene and protein expression data, these findings from human cells in vitro are consistent with those observed in the previous mouse model studies (2). Although the effect on glucose uptake is modest, this could be relevant in poorly controlled type 2 diabetes and provide a possible additional mechanism for glucotoxicity (39). These human data may also indicate that the effects on glucose tolerance may be unrelated to the normal physiological function of resistin, and its activity may be altered to an adaptive response to starvation, as previously suggested by Lazar and co-workers for the mouse model (2).
Although resistin inhibits glucose uptake and lipogenesis by human adipocytes, there was no detectable effect on basal rates of lipolysis, as noted by Lazar (2). This may relate to the lower concentrations of recombinant resistin used in our studies. In addition, despite chronic exposure to resistin, the protein failed to influence either lipid accumulation or leptin secretion in differentiating preadipocytes, which was also apparent with assessment of leptin and resistin vs. BMI in our nondiabetic cohort. Additional studies examining the effect of resistin on basal and catecholamine-stimulated lipolysis in isolated mature adipocytes may further define the contribution of resistin to increased free fatty acids as well as glucose intolerance, as both factors are associated with insulin resistance and type 2 diabetes. The observation that resistin regulates glucose metabolism in adipocytes, albeit weakly, and at low concentrations is consistent with a receptor-mediated signaling mechanism. The nature of the resistin receptor remains unknown.
In conclusion, serum resistin is increased in type 2 diabetic subjects, in whom it is also associated with elevated C-reactive protein, suggesting that this protein may be linked to subclinical inflammation. Furthermore, resistin is actively expressed and regulated by insulin and RSG in human abdominal adipose tissue in vitro, with RSG suppressing the insulin-mediated stimulation of resistin expression and secretion. Similar effects have been identified with other proinflammatory cytokines, including leptin, IL-6, and TNF (40, 41, 42, 43), suggesting that elevated resistin serum may be related to subclinical inflammation in diabetes, a hypothesis that requires further investigation. Finally, reduction of resistin secretion may be yet another mechanism by which TZDs improve insulin sensitivity.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Abbreviations: BMI, Body mass index; FIZZ, found in inflammatory zone; HbA1c, hemoglobin A1c; HOMA, homeostasis model assessment; LPS, lipopolysaccharide; RELM, resistin-like molecules; RSG, rosiglitazone; TZD, thiazolidinedione.
Received May 22, 2003.
Accepted September 3, 2003.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
action in humans. Diabetes 50:2199–2202 agonists. J Biol Chem 276:25651–25653 in adipose tissue. Mol Endocrinol 16:1920–1930 agonists. J Clin Invest 106:467–472[Medline]
activators. Biochem Biophys Res Commun 300:472–476[CrossRef][Medline]
in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11:212–217[CrossRef][Medline]This article has been cited by other articles:
 |
|
 |
|
  A. R. Baker, A. L. Harte, N. Howell, D. C. Pritlove, A. M. Ranasinghe, N. F. da Silva, E. M. Youssef, K. Khunti, M. J. Davies, R. S. Bonser, et al. Epicardial Adipose Tissue as a Source of Nuclear Factor-{kappa}B and c-Jun N-Terminal Kinase Mediated Inflammation in Patients with Coronary Artery Disease J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 261 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Qi, J. Wang, H. Li, Z. Yu, X. Ye, F. B Hu, O. H Franco, A. Pan, Y. Liu, and X. Lin Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese Eur. J. Endocrinol., November 1, 2008; 159(5): 585 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cohen, D. Ilic, J. Raupachova, and W. H. Horl Resistin Inhibits Essential Functions of Polymorphonuclear Leukocytes J. Immunol., September 15, 2008; 181(6): 3761 - 3768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Megia, J. Vendrell, C. Gutierrez, M. Sabate, M. Broch, J.-M. Fernandez-Real, and I. Simon Insulin sensitivity and resistin levels in gestational diabetes mellitus and after parturition Eur. J. Endocrinol., February 1, 2008; 158(2): 173 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ochi, H. Osawa, Y. Hirota, K. Hara, Y. Tabara, Y. Tokuyama, I. Shimizu, A. Kanatsuka, Y. Fujii, J. Ohashi, et al. Frequency of the G/G Genotype of Resistin Single Nucleotide Polymorphism at 420 Appears to Be Increased in Younger-Onset Type 2 Diabetes Diabetes, November 1, 2007; 56(11): 2834 - 2838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kos, A. L. Harte, S. James, D. R. Snead, J. P. O'Hare, P. G. McTernan, and S. Kumar Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1335 - E1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Krusinova, M Klementova, J Kopecky, P Wohl, L Kazdova, P Mlejnek, M Pravenec, M Hill, and T Pelikanova Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects Eur. J. Endocrinol., October 1, 2007; 157(4): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. McTernan and S. Kumar Retinol Binding Protein 4 and Pathogenesis of Diabetes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2430 - 2432. [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, M. J. Quon, Y. Lee, S. H. Han, J. Y. Ahn, W.-J. Chung, J.-a Kim, and E. K. Shin Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients Eur. Heart J., June 2, 2007; 28(12): 1440 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Knudson, G. M. Dick, and J. D. Tune Adipokines and Coronary Vasomotor Dysfunction Experimental Biology and Medicine, June 1, 2007; 232(6): 727 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Osawa, Y. Tabara, R. Kawamoto, J. Ohashi, M. Ochi, H. Onuma, W. Nishida, K. Yamada, J. Nakura, K. Kohara, et al. Plasma Resistin, Associated With Single Nucleotide Polymorphism -420, Is Correlated With Insulin Resistance, Lower HDL Cholesterol, and High-Sensitivity C-Reactive Protein in the Japanese General Population Diabetes Care, June 1, 2007; 30(6): 1501 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Senolt, D Housa, Z Vernerova, T Jirasek, R Svobodova, D Veigl, K Anderlova, U Muller-Ladner, K Pavelka, and M Haluzik Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum Ann Rheum Dis, April 1, 2007; 66(4): 458 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P F Dullaart, R. de Vries, A. van Tol, and W. J Sluiter Lower plasma adiponectin is a marker of increased intima-media thickness associated with type 2 diabetes mellitus and with male gender Eur. J. Endocrinol., March 1, 2007; 156(3): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kos, A. L. Harte, N. F. da Silva, A. Tonchev, G. Chaldakov, S. James, D. R. Snead, B. Hoggart, J. P. O'Hare, P. G. McTernan, et al. Adiponectin and Resistin in Human Cerebrospinal Fluid and Expression of Adiponectin Receptors in the Human Hypothalamus J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Creely, P. G. McTernan, C. M. Kusminski, ff. M. Fisher, N. F. Da Silva, M. Khanolkar, M. Evans, A. L. Harte, and S. Kumar Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E740 - E747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Kusminski, N. F. da Silva, S. J. Creely, F. M. Fisher, A. L. Harte, A. R. Baker, S. Kumar, and P. G. McTernan The in Vitro Effects of Resistin on the Innate Immune Signaling Pathway in Isolated Human Subcutaneous Adipocytes J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 270 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Dick, P. S. Katz, M. Farias III, M. Morris, J. James, J. D. Knudson, and J. D. Tune Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2997 - H3002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Qi, Z. Nie, Y.-S. Lee, N. S. Singhal, P. E. Scherer, M. A. Lazar, and R. S. Ahima Loss of Resistin Improves Glucose Homeostasis in Leptin Deficiency Diabetes, November 1, 2006; 55(11): 3083 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kunnari, O. Ukkola, M. Paivansalo, and Y. A. Kesaniemi High Plasma Resistin Level Is Associated with Enhanced Highly Sensitive C-Reactive Protein and Leukocytes J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2755 - 2760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Jung, K.-H. Park, Y. M. Cho, S. S. Chung, H. J. Cho, S. Y. Cho, S. J. Kim, S. Y. Kim, H. K. Lee, and K. S. Park Resistin is secreted from macrophages in atheromas and promotes atherosclerosis Cardiovasc Res, January 1, 2006; 69(1): 76 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Berggren, M. W. Hulver, and J. A. Houmard Fat as an endocrine organ: influence of exercise J Appl Physiol, August 1, 2005; 99(2): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gerber, A. Boettner, B. Seidel, A. Lammert, J. Bar, E. Schuster, J. Thiery, W. Kiess, and J. Kratzsch Serum Resistin Levels of Obese and Lean Children and Adolescents: Biochemical Analysis and Clinical Relevance J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4503 - 4509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ort, A. A. Arjona, J. R. MacDougall, P. J. Nelson, M. E. Rothenberg, F. Wu, A. Eisen, and Y.-D. C. Halvorsen Recombinant Human FIZZ3/Resistin Stimulates Lipolysis in Cultured Human Adipocytes, Mouse Adipose Explants, and Normal Mice Endocrinology, May 1, 2005; 146(5): 2200 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, and A. Tarkowski Resistin, an Adipokine with Potent Proinflammatory Properties J. Immunol., May 1, 2005; 174(9): 5789 - 5795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. von Eynatten, J. G. Schneider, S. Hadziselimovic, A. Hamann, A. Bierhaus, P. P. Nawroth, and K. A. Dugi Adipocytokines as a Novel Target for the Anti-inflammatory Effect of Atorvastatin in Patients With Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 754 - 755. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader Resistin Is an Inflammatory Marker of Atherosclerosis in Humans Circulation, February 22, 2005; 111(7): 932 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vozarova de Courten, M. Degawa-Yamauchi, R. V. Considine, and P. A. Tataranni High Serum Resistin Is Associated With an Increase in Adiposity But Not a Worsening of Insulin Resistance in Pima Indians Diabetes, May 1, 2004; 53(5): 1279 - 1284. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
